Safety and Efficacy of Lysergic Acid Diethylamide-Assisted-Psychotherapy for Anxiety Associated With Life-threatening Diseases Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, and Rudolf Brenneisen Journal of Nervous and Mental Diseases, 2014 Abstract : A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with lifethreatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 Kg of LSD (n = 8) or 20 Kg of LSD with an open-label crossover to 200 [...]
Lire la suiteLSD-Assisted Psychotherapy for Anxiety Related to Life-Threatening Illness Category: LSD-Assisted Psychotherapy: MAPS-Sponsored Clinical Trials Location: Solothurn, Switzerland MAPS is proud to sponsor the first study of the therapeutic use of LSD in humans in over 40 years. This study, based in Switzerland, investigates the safety and effectiveness of LSD-assisted psychotherapy in subjects with life-threatening illnesses and who are experiencing associated anxiety. The study received final approval from the BAG (the Swiss DEA) on December 5, 2007, final approval from the Ethics Committee (the Swiss IRB equivalent) on October 30, 2007, and clearance from SwissMedic (the Swiss FDA equivalent) on November 8, 2007. The [...]
Lire la suiteLSD-Assisted Psychotherapy https://maps.org/research/psilo-lsd MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s. LSD (lysergic acid diethylamide) is a semi-synthetic compound first developed in 1938 by Dr. Albert Hofmann at the Sandoz pharmaceutical company in Basel, Switzerland. After Dr. Hofmann first discovered its effects in 1943, LSD quickly became recognized for its possible therapeutic effects. LSD also played a significant role in the discovery of the serotonin neurotransmitter system. Experimental LSD capsule from our completed Swiss pilot study Our completed Phase 2 pilot study in 12 subjects found positive trends in the reduction of anxiety [...]
Lire la suiteMarijuana for Symptoms of PTSD in U.S. Veterans Category: MAPS-Sponsored Medical Marijuana Research https://maps.org/research/mmj/marijuana-us/ Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD) Site Principal Investigator: Sue Sisley, M.D. Coordinating Principal Investigator: Marcel Bonn-Miller, Ph.D. Co-Investigator: Paula Riggs, M.D. This study has completed enrollment. This study will explore whether smoked marijuana can help reduce PTSD symptoms in 76 U.S. veterans with chronic, treatment-resistant posttraumatic stress disorder (PTSD). Participants must be U.S. veterans, men or women, aged 18 or older with a diagnosis of PTSD that has not improved after [...]
Lire la suiteMedical Marijuana MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war. https://maps.org/research/mmj MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U.S. Food and Drug Administration. Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986. NIDA's previous monopoly on the supply of marijuana for research and the DEA's prior refusal to allow researchers to grow [...]
Lire la suiteUsing CBD to Tame a Cannabis High? Small Doses May Have the Opposite Effect Bailey Rahn, February 28, 2019, https://www.leafly.com Posted By Bailey Rahn On February 28, 2019 @ 3:52 pm In Science & Tech https://www.leafly.com/news/science-tech/how-cbd-dose-affects-cannabis-effects/print/ (imaginima/iStock) Take some CBD, they said. You’ll feel less high, they said. This common piece of advice fed to THC-shy consumers can effectively bring someone back down to earth. It works—sometimes. But new research shows there’s likely more nuance in the solution than we initially thought. Scientists found that a high dose of CBD dampened the effects of a THC high, but participants reported a stronger high when combined with low [...]
Lire la suiteLeafly : CBD in the Spotlight at SXSW, Despite Legal Gray Area Written by Tonyia Cone on March 26, 2019. Posted in MAPS in the Media Summary: A new article from Leafly reflects on the Cannabusiness session at South by South West (SXSW) 2019, where MAPS Policy and Advocacy Director Natalie Lyla Ginsberg, M.S.W., represented MAPS through participating in a panel discussion, The Future of Hemp and Health. Originally appearing here. A simple stroll across the festival grounds brought visitors past an array of CBD-focused booths: Kentucky-based MedTerra, for example, hosted a two-day, CBD-focused venue, dubbed “Wellhaus,” that featured a CBD infusion bar. [...]
Lire la suiteNo significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort) Fabienne MARCELLIN, Caroline LIONS, Eric ROSENTHAL, Perrine ROUX, Philippe SOGNI, Linda WITTKOP, Camelia PROTOPOPESCU, Bruno SPIRE, Dominique SALMON-CERON, François DABIS, Maria Patrizia CARRIERI, & HEPAVIH ANRS CO13 STUDY GROUP (10Paris Descartes University, Paris, France) Drug and Alcohol Review (2016) DOI: 10.1111/dar.12398 Abstract : Introduction and Aims. Despite cannabis use being very common in patients co-infected with HIV and hepatitis C virus (HCV), its effect on these patients’ immune systems remains undocumented. Documenting the potential effect of cannabis use on HIV immunological markers [...]
Lire la suiteAntidepressant-Like and Anxiolytic-Like Effects of Cannabidiol : A Chemical Compound of Cannabis sativa Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrión, José A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva CNS & Neurological Disorders - Drug Targets, 2014, 13, 953-960 Abstract : Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review [...]
Lire la suiteLe Chanvre (Cannabis Sativa), par booksofdante40 https://wp.me/p2SVqZ-1NL https://booksofdante.wordpress.com/2019/03/07/le-chanvre-cannabis-sativa/ Synonymes : chanevet, chanvret, canebier, cherve, chervet, chêne, chenove, etc. Le point de départ de l'histoire du chanvre se situe à mi-chemin entre la Turquie et la Chine, ce que l'on appellerait l'Asie centrale : cette zone d'origine comprend une partie de la Chine et du sous-continent indien, une portion iranienne et se compose enfin des ex républiques soviétiques que sont l'Ouzbékistan, le Turkménistan, l'Afghanistan, le Tadjikistan, le Kazakhstan et le Kirghizistan. A peu près. De là, il irradia tant vers la Chine orientale qu'en direction de l'ouest. En Chine, son usage médicinal remonte au moins au XV [...]
Lire la suite